Aligos Therapeutics, Inc (ALGS)

Etorro trading 970x250
Aligos Therapeutics, Inc (ALGS) Logo

About Aligos Therapeutics, Inc

Aligos Therapeutics, Inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB). The company is also developing ALG-000184, a capsid assembly modulator to treat CHB; ALG-020572, a oligonucleotide for the treatment of CHB; ALG-125097, an siRNA drug candidate to treat CHB; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis. Aligos Therapeutics, Inc. was founded in 2018 and is headquartered in South San Francisco, California. Address: One Corporate Drive, South San Francisco, CA, United States, 94080

Aligos Therapeutics, Inc News and around…

Latest news about Aligos Therapeutics, Inc (ALGS) common stock and company :

Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD’S The Liver Meeting® 2021
14 Oct, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced upcoming poster presentations highlighting data relating to its chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) clinical programs at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver D

Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study
11 Oct, 2021 Yahoo! Finance

Aligos now evaluating three of its four chronic hepatitis B (CHB) portfolio drug candidates in clinical trialsSOUTH SAN FRANCISCO, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has started dosing in the first cohort of healthy volunteers in Study ALG-020572-401 (NCT05001022). The tria

Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
20 Sep, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021
09 Sep, 2021 FinancialContent

Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE:BLD) was changed from Hold to Buy. In the ...

Analysts See 17% Gains Ahead For The Holdings of PBSM
09 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco PureBeta MSCI USA Small Cap ETF (PBSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $45.82 per unit.

How The Pieces Add Up: VHT Targets $283
09 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $283.00 per unit.

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results
05 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
01 Aug, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingJuly 30 amid earnings releases from big pharma companies. Most ...

Aligos Therapeutics to Announce Second Quarter 2021 Results August 5, 2021
29 Jul, 2021 FinancialContent
Analysts Expect VTWV To Hit $157
08 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $156.76 per unit.

Companies Like Aligos Therapeutics (NASDAQ:ALGS) Are In A Position To Invest In Growth
06 Jul, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Investors Snatch ALGS 12.3% Cheaper Than Its Secondary Stock Offering
02 Jul, 2021 FinancialContent

Looking back to 2 days ago, Aligos Therapeutics Inc (ALGS) priced a 4,400,000 share secondary stock offering at $19.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time..

58 Biggest Movers From Yesterday
02 Jul, 2021 FinancialContent

Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its ...

Mid-Afternoon Market Update: Dow Gains 100 Points; NovoCure Shares Plunge
01 Jul, 2021 FinancialContent

Toward the end of trading Thursday, the Dow traded up 0.29% to 34,603 while the NASDAQ rose 0.01% to 14,504.68. The S&P also rose, ...

12 Health Care Stocks Moving In Thursday's Intraday Session
01 Jul, 2021 FinancialContent

Gainers Alterity Therapeutics (NASDAQ:ATHE) shares increased by 60.0% to $2.08 during Thursday's regular session. Trading volume for ...

Mid-Day Market Update: Crude Oil Rises Over 2%; Aligos Therapeutics Shares Slide
01 Jul, 2021 FinancialContent

Midway through trading Thursday, the Dow traded up 0.20% to 34,571.92 while the NASDAQ fell 0.24% to 14,468.72. The S&P also rose, ...

30 Stocks Moving In Thursday's Mid-Day Session
01 Jul, 2021 FinancialContent

Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 104.6% to $62.00. Pop Culture Group shares jumped 405% on ...

Aligos Therapeutics is Now Oversold (ALGS)
01 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Aligos Therapeutics Raises $84M Via Equity At 7% Discount
01 Jul, 2021 FinancialContent

Aligos Therapeutics Inc(NASDAQ: ALGS) has priced apreviously announcedunderwritten public offering of4.4 ...

Aligos Therapeutics Announces Pricing of $83.6 Million Public Offering of Common Stock
01 Jul, 2021 FinancialContent
35 Stocks Moving In Tuesday's Mid-Day Session
29 Jun, 2021 FinancialContent

Gainers Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) shares jumped 111.5% to $26.58 after the company announced positive ...

Aligos Therapeutics Presses Capital Raise Button
29 Jun, 2021 FinancialContent

Aligos Therapeutics Inc(NASDAQ: ALGS) commenced an underwrittenpublic offering of 4 million sharesof common ...

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
29 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

22 Stocks Moving in Tuesday's Pre-Market Session
29 Jun, 2021 FinancialContent

Gainers Exela Technologies, Inc. (NASDAQ: XELA) rose 39% to $2.05 in pre-market trading after gaining over 5% on Monday. Marin ...

Aligos Therapeutics Announces Proposed Public Offering of Common Stock
28 Jun, 2021 FinancialContent
Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association fo
21 Jun, 2021 FinancialContent
Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133 and Several Nonclinical Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
21 Jun, 2021 Yahoo! Finance

-First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients-Presentations include nonclinical data from 3 other CHB programs SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that a poster describing preliminary

Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
14 Jun, 2021 FinancialContent
The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal
10 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Aligos Therapeutics, Inc (ALGS) is a NASDAQ Common Stock listed in , ,

970x250